IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL)
Here, we report interim results from ZUMA-5, a Phase 2 study of axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed/refractory iNHL. Adults with relapsed/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL) after ≥2 lines of thera...
Uložené v:
| Vydané v: | Clinical lymphoma, myeloma and leukemia Ročník 20; s. S278 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Elsevier Inc
01.09.2020
|
| Predmet: | |
| ISSN: | 2152-2650, 2152-2669 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Here, we report interim results from ZUMA-5, a Phase 2 study of axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed/refractory iNHL.
Adults with relapsed/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL) after ≥2 lines of therapy (including an anti-CD20 monoclonal antibody with an alkylating agent) were eligible. Patients were leukapheresed and received conditioning chemotherapy followed by axi-cel at 2 × 106 CAR T cells/kg. The primary endpoint was objective response rate (ORR) by central review (Cheson, et al. J Clin Oncol. 2014). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), safety, and blood levels of CAR T cells.
As of 8/20/19, 94 patients (80 FL; 14 MZL) received axi-cel (median follow-up, 11.5 months). Median age was 63 years, 51% of patients had ≥3 FLIPI, 59% had high tumor bulk, 66% progressed < 2 years after first chemoimmunotherapy (POD24), and 73% were refractory to the last treatment. Of 87 patients evaluable for efficacy, ORR was 94% (79% complete response [CR] rate). Patients with FL (n=80) had an ORR of 95% (80% CR rate). Patients with MZL (n=7) had an ORR of 86% (71% CR rate). Overall, 68% of patients had ongoing responses as of the data cutoff. Updated data will be presented. Of 94 patients evaluable for safety, 83% experienced Grade ≥ 3 adverse events, most commonly neutropenia (33%) and anemia (28%). Grade ≥ 3 cytokine release syndrome (CRS) and neurologic events (NEs) occurred in 11% and 19% of patients, respectively. Median times to onset of CRS and NEs were 4 and 7 days; median durations were 6 and 14.5 days. There were 2 Grade 5 adverse events: multisystem organ failure in the context of CRS (related to axi-cel) and aortic dissection (unrelated to axi-cel). Median peak and AUC0-28 CAR T cell levels were 44 cells/μL and 490 cells/μL × day, respectively.
Axi-cel showed significant clinical benefit, with high response rates, and a manageable safety profile in patients with relapsed/refractory iNHL. Funding provided by Kite, a Gilead Company. |
|---|---|
| AbstractList | Here, we report interim results from ZUMA-5, a Phase 2 study of axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed/refractory iNHL.
Adults with relapsed/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL) after ≥2 lines of therapy (including an anti-CD20 monoclonal antibody with an alkylating agent) were eligible. Patients were leukapheresed and received conditioning chemotherapy followed by axi-cel at 2 × 106 CAR T cells/kg. The primary endpoint was objective response rate (ORR) by central review (Cheson, et al. J Clin Oncol. 2014). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), safety, and blood levels of CAR T cells.
As of 8/20/19, 94 patients (80 FL; 14 MZL) received axi-cel (median follow-up, 11.5 months). Median age was 63 years, 51% of patients had ≥3 FLIPI, 59% had high tumor bulk, 66% progressed < 2 years after first chemoimmunotherapy (POD24), and 73% were refractory to the last treatment. Of 87 patients evaluable for efficacy, ORR was 94% (79% complete response [CR] rate). Patients with FL (n=80) had an ORR of 95% (80% CR rate). Patients with MZL (n=7) had an ORR of 86% (71% CR rate). Overall, 68% of patients had ongoing responses as of the data cutoff. Updated data will be presented. Of 94 patients evaluable for safety, 83% experienced Grade ≥ 3 adverse events, most commonly neutropenia (33%) and anemia (28%). Grade ≥ 3 cytokine release syndrome (CRS) and neurologic events (NEs) occurred in 11% and 19% of patients, respectively. Median times to onset of CRS and NEs were 4 and 7 days; median durations were 6 and 14.5 days. There were 2 Grade 5 adverse events: multisystem organ failure in the context of CRS (related to axi-cel) and aortic dissection (unrelated to axi-cel). Median peak and AUC0-28 CAR T cell levels were 44 cells/μL and 490 cells/μL × day, respectively.
Axi-cel showed significant clinical benefit, with high response rates, and a manageable safety profile in patients with relapsed/refractory iNHL. Funding provided by Kite, a Gilead Company. |
| Author | Yang, Yin Casulo, Carla Lee, Jennifer Plaks, Vicki Fung, Henry C. Vos, Sven de Leslie, Lori A. Maloney, David G. William, Basem M. Yakoub-Agha, Ibrahim Salles, Gilles Reshef, Ran Chavez, Julio C. Jacobson, Caron A. Sehgal, Alison R. Munshi, Pashna N. Neelapu, Sattva S. Oluwole, Olalekan O. Avanzi, Mauro P. Munoz, Javier |
| Author_xml | – sequence: 1 givenname: Caron A. surname: Jacobson fullname: Jacobson, Caron A. organization: Dana-Farber Cancer Institute, Boston, MA, USA – sequence: 2 givenname: Julio C. surname: Chavez fullname: Chavez, Julio C. organization: University of South Florida H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA – sequence: 3 givenname: Alison R. surname: Sehgal fullname: Sehgal, Alison R. organization: UPMC Hillman Cancer Center, Pittsburgh, PA, USA – sequence: 4 givenname: Basem M. surname: William fullname: William, Basem M. organization: The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA – sequence: 5 givenname: Javier surname: Munoz fullname: Munoz, Javier organization: Banner MD Anderson Cancer Center, Gilbert, AZ, USA – sequence: 6 givenname: Gilles surname: Salles fullname: Salles, Gilles organization: Centre Hospitalier Lyon Sud, Pierre-Bénite, France – sequence: 7 givenname: Carla surname: Casulo fullname: Casulo, Carla organization: University of Rochester Medical Center - James P. Wilmot Cancer Center, Rochester, NY, USA – sequence: 8 givenname: Pashna N. surname: Munshi fullname: Munshi, Pashna N. organization: Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA – sequence: 9 givenname: David G. surname: Maloney fullname: Maloney, David G. organization: Fred Hutchinson Cancer Research Center, Seattle, WA, USA – sequence: 10 givenname: Sven de surname: Vos fullname: Vos, Sven de organization: Ronald Reagan University of California Los Angeles Medical Center, Santa Monica, CA, USA – sequence: 11 givenname: Ran surname: Reshef fullname: Reshef, Ran organization: Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, USA – sequence: 12 givenname: Lori A. surname: Leslie fullname: Leslie, Lori A. organization: John Theurer Cancer Center, Hackensack, NJ, USA – sequence: 13 givenname: Ibrahim surname: Yakoub-Agha fullname: Yakoub-Agha, Ibrahim organization: Centre Hospitalier Régional Universitaire de Lille, Lille, France – sequence: 14 givenname: Olalekan O. surname: Oluwole fullname: Oluwole, Olalekan O. organization: Vanderbilt University Medical Center, Nashville, TN, USA – sequence: 15 givenname: Henry C. surname: Fung fullname: Fung, Henry C. organization: Fox Chase Cancer Center, Philadelphia, PA, USA – sequence: 16 givenname: Vicki surname: Plaks fullname: Plaks, Vicki organization: Kite, a Gilead Company, Santa Monica, CA, USA – sequence: 17 givenname: Yin surname: Yang fullname: Yang, Yin organization: Kite, a Gilead Company, Santa Monica, CA, USA – sequence: 18 givenname: Jennifer surname: Lee fullname: Lee, Jennifer organization: Kite, a Gilead Company, Santa Monica, CA, USA – sequence: 19 givenname: Mauro P. surname: Avanzi fullname: Avanzi, Mauro P. organization: Kite, a Gilead Company, Santa Monica, CA, USA – sequence: 20 givenname: Sattva S. surname: Neelapu fullname: Neelapu, Sattva S. organization: The University of Texas MD Anderson Cancer Center, Houston, TX, USA |
| BookMark | eNqNkcFuEzEQhleoSLSFR0DyMTkssb3ZzW4RQssKSKSlVCm9cLEm3nFj6tiR7QL7RjwmTltx6KVc7JFH3z-azyfZkXUWs-w1o28YZdXskrOS57wq6YTTaUHrps6LZ9nxw3PVHP2rS_oiOwnhB6ULSllznP1Zfej6nPH5GVnZiF7vSGvBjEEH4hT5fvWlzcsz0pKLLQQknFzG22E8tNrfWsImwjVaJJ02zuCtREMmqZF3aKZEW3IBUaONgfzScUvWaGAfcJitUXmQ0fkxTR0SaSM5dzZfuuH6JmH9uNtv3Q7IZD1bE32-7Kcvs-cKTMBXD_dpdvXp47dumfdfP6-6ts8lp3WRc1UsSmSqnqeKwmKOCpScA1cNVIBQKuBYoWJNUTWqLhe4gaFUrJLpUHxTnGblfa70LgSPSuyTFPCjYFQcdIs73eLgUnAq7nSLInFvH3FSx7S9s9GDNk_S7-9pTKv91OhFkEmcxEF7lFEMTj-Z8O5RgjTapi8yNzj-B_8XMKuuNw |
| CitedBy_id | crossref_primary_10_1111_bjh_19064 crossref_primary_10_1016_S1773_035X_21_00143_X crossref_primary_10_1007_s11899_021_00614_8 crossref_primary_10_1136_jitc_2023_007515 crossref_primary_10_1188_21_CJON_255_258 |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier Inc. |
| Copyright_xml | – notice: 2020 Elsevier Inc. |
| DBID | AAYXX CITATION |
| DOI | 10.1016/S2152-2650(20)30898-3 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2152-2669 |
| EndPage | S278 |
| ExternalDocumentID | 10_1016_S2152_2650_20_30898_3 S2152265020308983 |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1P~ 1~. 4.4 457 4G. 53G 5VS 6PF 7-5 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV C45 CAG COF DU5 EBS EFJIC EFKBS EFLBG EJD EMOBN F5P FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM M41 MET MO0 O-L O9- OAUVE OC~ OO- OVD P-8 P-9 PC. Q38 ROL SDF SEL SES SPCBC SSH SSZ T5K TEORI XH2 Z5R ~G- ~HD AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW EMB LCYCR SV3 AAYXX CITATION |
| ID | FETCH-LOGICAL-c2083-2f375e1f842f30a74efafc4a2f9a6aea5fa2e6ef19369f857ebad5f16c5f1f2b3 |
| ISSN | 2152-2650 |
| IngestDate | Wed Nov 05 20:43:56 EST 2025 Tue Nov 18 21:55:32 EST 2025 Fri Feb 23 02:46:15 EST 2024 Tue Oct 14 19:30:16 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | IBCL chimeric antigen receptor CAR T cell therapy indolent B-cell lymphoma |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c2083-2f375e1f842f30a74efafc4a2f9a6aea5fa2e6ef19369f857ebad5f16c5f1f2b3 |
| ParticipantIDs | crossref_primary_10_1016_S2152_2650_20_30898_3 crossref_citationtrail_10_1016_S2152_2650_20_30898_3 elsevier_sciencedirect_doi_10_1016_S2152_2650_20_30898_3 elsevier_clinicalkey_doi_10_1016_S2152_2650_20_30898_3 |
| PublicationCentury | 2000 |
| PublicationDate | September 2020 2020-09-00 |
| PublicationDateYYYYMMDD | 2020-09-01 |
| PublicationDate_xml | – month: 09 year: 2020 text: September 2020 |
| PublicationDecade | 2020 |
| PublicationTitle | Clinical lymphoma, myeloma and leukemia |
| PublicationYear | 2020 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| SSID | ssj0070019 |
| Score | 2.213316 |
| Snippet | Here, we report interim results from ZUMA-5, a Phase 2 study of axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients... |
| SourceID | crossref elsevier |
| SourceType | Enrichment Source Index Database Publisher |
| StartPage | S278 |
| SubjectTerms | CAR T cell therapy chimeric antigen receptor IBCL indolent B-cell lymphoma |
| Title | IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL) |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2152265020308983 https://dx.doi.org/10.1016/S2152-2650(20)30898-3 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 2152-2669 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0070019 issn: 2152-2650 databaseCode: AIEXJ dateStart: 20100601 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bT9swFLagTNNeJnYT7CY_7KGoSkmdm8NbV4EKggq1IKG9RE6woSJNUNsh-Ef7mTsnttOgTWKbtBcrjX3iKOdrziXnQsgXN-Vp5nHh9PyAOX4MNmsqRexkUZy6aepfMldVzSai0YhfXMSna-ubNhfmLo-Kgt_fx7f_ldVwDpiNqbN_we76onACjoHpMALbYfwjxh9-HRw7IE_R1q_8fdPZo9Ij385P-k6gM9JPr0GIdVgVTVh9au_fA9PSJbxkQPkcTPMyl8D7HPVQmHIG-E0_Rh_Jqa7HapLjMKTudoF-04OxVPOqh88D7I7looplZ1QWzrC8vLoBwuMHwE85E5XvAtd3pqPhsXVI2JoJNl8zN6sRCbMHmSMhuvrhtm7kbFrLlCN4sdtO6BjDUnT63Ubkwp32k2MyeNkZ1DMTeX0ldJRCXrViHNdTxg-lP8ks5Kxz0m06SMAathFgxmtnM3ceBZZiO1-HhbrobVc2z-nWMVY6MLfxep8w3W_IqAr25y9iSHtEJvUm8EQZDLHn8pg73kr21hGR1VpcytxqkbdONlgUxLxFNvqH-xdHVr3AOAG06eprr9LSdlcbtpm7Yzb7vcLVUKLONslLY_3QvkbtK7Imi9fk-YmJ73hDfljw7lEDXWqhS0tFNXT3aJ9WwKWMVsDFqSZw6Qq4tG1gu0OnBbWgpQhaakG7u4IstZClDchSC1naHu-OKcJ15y05P9g_Gwwd00vEyRhYGQ5TXhTInuI-HLki8qUSKvMFU7EIhRSBEkyGUvWwwaXiQSRTcRmoXpjBoFjqvSOtoizkFqFgwaSe5G4gQwXqcADXCCOmBA8DIEz5NvHtA08yU2gf-73kSR1RiXxKkE8Jc5OKT4m3Tbo12a2uNPMUQWi5mdg0ahD8CYDwKUJeExo9W-vPT5O-_3fSD-TF6t_5kbSW8-_yE3mW3S2ni_lng_KfhlXo4g |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=IBCL-124%3A+Interim+Analysis+of+ZUMA-5%3A+A+Phase+2+Study+of+Axicabtagene+Ciloleucel+%28Axi-Cel%29+in+Patients+with+Relapsed%2FRefractory+Indolent+Non-Hodgkin+Lymphoma+%28R%2FR+iNHL%29&rft.jtitle=Clinical+lymphoma%2C+myeloma+and+leukemia&rft.au=Jacobson%2C+Caron+A.&rft.au=Chavez%2C+Julio+C.&rft.au=Sehgal%2C+Alison+R.&rft.au=William%2C+Basem+M.&rft.date=2020-09-01&rft.pub=Elsevier+Inc&rft.issn=2152-2650&rft.eissn=2152-2669&rft.volume=20&rft.spage=S278&rft.epage=S278&rft_id=info:doi/10.1016%2FS2152-2650%2820%2930898-3&rft.externalDocID=S2152265020308983 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2152-2650&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2152-2650&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2152-2650&client=summon |